title: Mechanism of action of epidermal growth factor-induced porcine oocyte maturation.
abstract: EGF has been reported to promote oocyte maturation in several species, although the mechanism of action is not yet known. The present study is designed to determine the pathway used by EGF to enhance porcine oocyte maturation. Oocytes were aspirated from 2-5 mm follicles and cultured with various treatments in Medium-199 at 37 degrees C, 100% relative humidity, and 5% CO2 for 48 hr for the maturation study and 3 hr for intracellular cAMP measurement. Although treatment with 100 IU/ml hCG stimulated both intracellular cAMP formation and oocyte maturation, 10 ng/ml EGF stimulated oocyte maturation only. Dibutyryl cAMP (dbcAMP) inhibited oocyte maturation at 10(-5), 10(-4), and 10(-3) M concentration s in the control medium. However, in the presence of 10 ng/ml EGF, dbcAMP inhibited oocyte maturation only at a concentration of 10(-3) M. Increasing concentrations of EGF (i.e., 25 and 50 ng/ml) were ineffective in overcoming the inhibitory effect of dbcAMP at 10(-3) M. In contrast, EGF reversed the decreased maturation rate caused by transforming growth factor-beta. Phorbol myristate acetate (PMA), a tumor-promoting phorbol ester, enhanced the spontaneous maturation rate; 4 alpha-phorbol dideconoate, an inactive phorbol ester, did not show this effect. PMA- and EGF-stimulated porcine oocyte maturation is reversed by calphostin-C, a PKC inhibitor. In conclusion, EGF's promotional activity on porcine oocyte maturation is independent of the cAMP pathway and probably mediated by the PKC pathway.
authors.affiliation: Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine, Ohio State University, Columbus 43210-1092, USA.
authors.forename: S
authors.initials: S
authors.lastname: Coskun
authors.forename: Y C
authors.initials: YC
authors.lastname: Lin
mesh_terms: D000818:Animals; D003994:Bucladesine / Q000031:analogs & derivatives / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D051379:Mice; D009281:Naphthalenes / Q000494:pharmacology; D009865:Oocytes / Q000187:drug effects / Q000502:physiology; D009866:Oogenesis / Q000187:drug effects*; D010703:Phorbol Esters / Q000494:pharmacology; D013552:Swine; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D016212:Transforming Growth Factor beta / Q000494:pharmacology
chemical_list: D009281:Naphthalenes; D010703:Phorbol Esters; D016212:Transforming Growth Factor beta; C008876:phorbol-12,13-didecanoate; C007328:N(6)-2'-O-dibutyryl-8-thiocyclic AMP; D004815:Epidermal Growth Factor; D003994:Bucladesine; D000242:Cyclic AMP; C058819:calphostin C; D013755:Tetradecanoylphorbol Acetate